Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy
<b>Background:</b> The therapeutic management of immune-mediated thrombotic thrombocytopenic purpura (iTTP) has recently benefited from the introduction of caplacizumab, an agent directed at the inhibition of platelet aggregation. This real-world analysis investigated the epidemiology an...
Main Authors: | Emanuele Angelucci, Andrea Artoni, Luana Fianchi, Melania Dovizio, Biagio Iacolare, Stefania Saragoni, Luca Degli Esposti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/13/5/1342 |
Similar Items
-
Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura
by: Jon Shaffer, et al.
Published: (2022-07-01) -
Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience
by: Brandon Tse, et al.
Published: (2023-12-01) -
Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
by: Constantine N. Logothetis, et al.
Published: (2021-07-01) -
Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
by: Rodgers GM, et al.
Published: (2023-03-01) -
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
by: Francesca Palandri, et al.
Published: (2021-12-01)